Description

Poly(glycolic acid)

Poly(glycolic acid) (PGA) is a pharmaceutical-grade, biodegradable aliphatic polyester widely used in bioresorbable implants, surgical sutures, controlled drug delivery systems, and tissue engineering scaffolds. Known for its high crystallinity, mechanical strength, and rapid hydrolytic degradation, PGA is a core material for short-term resorbable medical devices and fast-degrading controlled-release formulations. PGA

• Is a pharmaceutical-grade, high-purity biodegradable polyester
• Is fully biocompatible, hydrolytically degrading into glycolic acid
• Has high tensile strength and crystallinity for implantable device applications
• Offers a rapid degradation profile for short-acting controlled-release formulations

Poly(glycolic acid) is synthesized via ring-opening polymerization of glycolide, producing a highly crystalline polymer with superior mechanical properties and predictable hydrolytic breakdown. Upon implantation or exposure to aqueous environments, PGA rapidly hydrolyzes into glycolic acid, which is safely metabolized through natural physiological pathways.

In pharmaceutical controlled-release formulations, PGA is used to develop fast-degrading microspheres, injectable depots, and bioresorbable drug-eluting implants, where shorter release durations are desirable for localized or systemic drug delivery.

In biomedical applications, Poly(glycolic acid) serves as a key material for bioresorbable sutures, fixation devices, orthopedic implants, bone repair scaffolds, and wound healing matrices. Its rapid breakdown profile supports temporary mechanical support while promoting tissue healing and eliminating the need for implant removal.

Procurement teams and formulation scientists seeking to purchase Poly(glycolic acid) benefit from CarboMer’s tightly controlled molecular weight specifications, validated manufacturing processes, and full regulatory support for global product registration.

The material is supplied in sealed, moisture-protected packaging to maintain long-term stability during storage and transportation. Minimum order quantities (MOQ), lead times, and full regulatory documentation are available to support preclinical, clinical, and commercial development programs.

Each production batch undergoes validated analytical testing for molecular weight distribution, crystallinity, residual monomers, heavy metals, and microbial purity to ensure full regulatory compliance and batch-to-batch consistency.

As with all CarboMer biomaterials and excipients, Poly(glycolic acid) is fully supported by technical consulting, formulation development assistance, and regulatory expertise to streamline pharmaceutical development from early-stage R&D through global commercialization.